Stay updated with breaking news from Evaluate Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...
The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.
/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the European Commission has approved TAKHZYRO® (lanadelumab) for the routine prevention of recurrent...
- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age...
- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six.